

# 20년 전통의 제약 남미 브랜드





## 20

이 회사는 19년 동안 콜롬비아 시장에 진출했으며 승인된 INVIMA 등록을 소유하고 있습니다.

하나의 대형 유통업체와 함께 과테말라와 중미의 5개국으로 시장을 확장하기 위한 진지한 대화가 있습니다. 콜롬비아의 모든 주요 도시와 많은 보조 도시에 289개의 제휴 약국이 있습니다. CRM은 의사, 약국 및 기관 시장 사이에 1397명의 회원으로 매우 잘 조직되어 있습니다. 콜롬비아의 모든 주요 도시와 많은 보조 도시에 289개의 제휴 약국이 있습니다.

### 상업 시장

- 매출의 75%가 의사를 통해 이루어집니다.
- 매출의 25%가 기관

회사는 API, 부형제, 포장 및 제품을 구매하고 모든 것은 INVIMA에서 승인한 콜롬비아의 전문 공장에서 아웃소싱하여 만듭니다.

현재 INVIMA와 산업통상청에 의해 등록 및 승인된 32개의 제품이 있습니다. INVIMA는 두 가지 신제품을 승인할 예정입니다.

콜롬비아 INVIMA의 승인에는 평균 2년이 소요되고 미화 \$30.000의 투자가 필요합니다.

이 사업에는 5가지 영양 제품이 있으며 그 중 우리는 브랜드를 소유하고 있지만 등록 기관은 아닙니다.

### 제품

- o 항생제
- o 진통제
- o 항염증제
- o 항히스타민제
- o 심혈관
- o 영양
- o 위장병학
- o 지질 저하제
- o 소아용 제품: 항생제 및 영양제.

### TARGET PRICE

\$11,500,000

### GROSS REVENUE

\$2,000,000

### EBITDA

\$450,000

### BUSINESS TYPE

제조업

### ESTABLISHED

2002-06-22

### SUPPORT & TRAINING

6 개월

### REASON FOR SELLING

퇴직

### COUNTRY

콜롬비아

### BUSINESS ID

L#20210109

*The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction*

*The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.*

*By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.*

*This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.*

*The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.*

*All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.*

[www.mergerscorp.com](http://www.mergerscorp.com)



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



[WWW.MERGERSCORP.COM](http://WWW.MERGERSCORP.COM)